TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: Main Inclusion Criteria:~1. Is male or female and ≥18 and \<75 years old at time of informed consent.~2. Has a HbA1c of ≥7.5% and ≤10.5% based on central laboratory results from Visit 1, with individual need for therapy escalation.~3. Currently treated with a stable maximum tolarated dose (MTD) (≥1500 mg/day) of metformin therapy for at least 8 weeks prior to Enrolment visit.~4. Has a BMI of ≤45 kg/m2 at Enrolment visit.~5. Has a C-peptide laboratory value of ≥1.0 ng/mL (0.33 nmol/L; 333.3 pmol/L) based on central laboratory results from Visit 1.~Main, Exclusion Criteria:~1. Clinically diagnosed with Type I diabetes, known diagnosis of maturity onset diabetes of the young (MODY), or secondary diabetes mellitus or known presence of glutamate decarboxylase 65 (GAD65) antibodies.~2. Patients who, in the judgment of the Investigator, may be at risk for dehydration or volume depletion that may affect the patient's safety and/or the interpretation of efficacy or safety data.~3. Clinically significant cardiovascular disease or procedure within 3 months prior to Enrolment or expected to require coronary revascularization procedure during the course of the study.~4. Concomitant treatment with loop diuretics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin+metformin (Type: ACTIVE_COMPARATOR): Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin
- Dapagliflozin+saxagliptin+metformin (Type: ACTIVE_COMPARATOR): Dapagliflozin + saxagliptin + glimepiride placebo+ metformin
- Glimepiride+metformin (Type: ACTIVE_COMPARATOR): Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers over 18 years of age.~Exclusion Criteria:~* Any medical condition.~* Any drug treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- GLP-1 (Type: EXPERIMENTAL): Intravenous infusion of GLP-1 at 0.7 and 1.2 mol/kg per minute
- Control (Type: PLACEBO_COMPARATOR): Intravenous saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must have BMI \>=30 kg/m2 and \<50 kg/m2 at screening or BMI \>=27 kg/m2 and \<50 kg/m2 at screening in the presence of a comorbidity of hypertension and/or dyslipidemia~* Must have stable weight, ie, change of \< =5% in the 3 months before screening~* Must agree to utilize a highly effective method of birth control~Exclusion Criteria:~* An established diagnosis of diabetes mellitus~* Has a history of obesity with a known secondary cause (eg, Cushing's disease/syndrome)~* Has a history of hereditary glucose-galactose malabsorption or primary renal glycosuria~* Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident within 12 weeks before screening~* Has an Glycated hemoglobin (HBA1c) greater than or equal (\>=) to 65 percent~* An average of 3 seated blood pressure (BP) readings of systolic BP \>= 160 mm Hg and/or Diastolic BP \>= 100 millimeters of mercury at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin + Phentermine (Type: EXPERIMENTAL): 300 mg capsule of Canagliflozin along with 15 mg capsule of Phentermine, taken once daily, orally for 26 weeks.
- Canagliflozin + Placebo (Phentermine) (Type: EXPERIMENTAL): 300 mg capsule of Canagliflozin along with matching placebo to Phentermine, taken once daily, orally for 26 weeks.
- Phentermine + Placebo (Canagliflozin) (Type: EXPERIMENTAL): 15 mg capsule of Phentermine along with matching placebo to Canagliflozin, taken once daily, orally for 26 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to Canagliflozin and Phentermine, taken once daily, orally for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy of Full-mouth Disinfection in Generalized Aggressive Periodontitis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* No systemic diseases that could influence the outcome of the therapy~* No smoking~* No medications affecting periodontal tissues~* No pregnancy or lactation~* Presence of at least 15 teeth~Exclusion Criteria:~* Received antibiotic treatment in the previous 3 months~* Smokers~* Pregnancy and lactation~* Received periodontal treatment in the previous 6 months~* Presence of less than 15 teeth~* Presence of systemic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Full-mouth Disinfection IPT (Type: ACTIVE_COMPARATOR): Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
- Conventional IPT (Type: EXPERIMENTAL): Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
- Full-mouth IPT (Type: EXPERIMENTAL): Initial periodontal treatment was performed in 2 sessions within 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* elective coronary artery bypass grafting operation (CABG)~* decreased left ventricular (LV) systolic function (EF LV ≤ 50%)~* Age 18 to 85~* Signed informed consent~* Females with childbearing potential have to use appropriate contraceptive measures during the whole study period and 6 months after terminating exenatide infusion (hormonal contraception or double-barrier contraception for both partners)~Exclusion Criteria:~* allergy to exenatide~* allergy to insulin~* mental incapacity or language barrier~* use of incretin-based therapies \<3 months before inclusion in the study~* diabetic ketoacidosis~* established autonomic neuropathy~* history of acute pancreatitis or severe disease of digestive tract~* renal failure (preoperative creatinine ≥ 180 umol/l)~* liver failure (coagulation times more than 1.5 times higher without use of anticoagulants)~* cardiac surgical procedure on valve, thoracic aorta or MAZE procedure~* pregnancy and lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving perioperatively i.v. exenatide on top of standard treatment
- Control (Type: NO_INTERVENTION): Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Conditioned Serum: Functional and Clinical Results

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* knee osteoarthritis \>3 months in clinical and radiographic signs~* VAS for pain \>50mm~Exclusion Criteria:~* Hepatitis B~* Hepatitis C~* HIV~* pregnancy~* drug abuse~* other intra-articular injections \<6 months~* surgery on affected knee \<12 months

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autologous Conditioned Serum (Type: EXPERIMENTAL): Patients that were deemed admissible to the trial received 1 intra-articular injection of autologous conditioned serum (Orthokine®) for 4 consecutive weeks at the site of OA. These patients were then followed at 1 month and 6 months for clinical and functional evaluation using VAS for pain, WOMAC, and KSS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of DU-176b Aged 80 Years or Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Nonvalvular Atrial Fibrillation (NVAF) aged 80 years or older who are ineligible for available oral anticoagulation therapy~Exclusion Criteria:~* Patients with active bleeding~* Patients who have poorly controlled hypertension~* Patients who have liver dysfunction accompanied with disorder of blood coagulation

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DU-176b 15 mg group (Type: EXPERIMENTAL): DU-176b orally administered at a dose of 15 mg once daily.
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo orally administered once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of type 2 diabetes mellitus prior to informed consent;~2. Male and female patients on diet and exercise regimen who are drug-naïve;~3. HbA1c \>= 7.0% and \<= 10.0% at Visit 1 (screening) for randomised treatment; HbA1c \> 10.0% at visit 1 (screening) for the open-label BI 10773 arm;~4. Age \>= 20 (Japan); Age \>= 18 (countries other than Japan);~5. BMI \<= 45 kg/m2 at Visit 1 (screening);~6. Signed and dated written informed consent by date of Visit 1~Exclusion criteria:~1. Uncontrolled hyperglycaemia;~2. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or TIA within 3 months prior to informed consent;~3. Indication of liver disease, either ALT, AST, or alkaline phosphatase above 3 x ULN;~4. Impaired renal function (eGFR\<50 ml/min);~5. Bariatric surgery within the past two years or other GI surgeries;~6. Medical history of cancer;~7. Contraindications to sitagliptin;~8. Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell;~9. Treatment with any anti-diabetes drug within 12 weeks prior to randomisation;~10. Treatment with anti-obesity drugs or any other treatment leading to unstable body weight;~11. Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM;~12. Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and not practicing an acceptable method of birth control;~13. Alcohol or drug abuse;~14. Intake of an investigational drug in another trial within 30 days prior to intake of study medication in this trial;~15. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): Patients receive BI 10773 low dose tablets once daily
- BI 10773 high dose (Type: EXPERIMENTAL): Patients receive BI 10773 high dose tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): Patients receive Sitagliptin 100 mg tablets once daily
- BI 10773 high dose open label (Type: EXPERIMENTAL): Patients receive BI 10773 high dose tablets open label once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* You must have confirmed metastatic or advanced cancer that has not responded to standard therapy or where standard therapy does not exist~* In Part C, patients must have a diagnosis of advanced or metastatic colorectal adenocarcinoma or non-small cell lung cancer, and must have received at least 1 but no more than three prior systemic therapy treatment regimens~* You must be over the age of 18 years old~* You must have a ECOG status performance of 0 or 1~* You must have good organ function~* You must be willing to have skin and/or tumor biopsies~Exclusion Criteria:~* You have had cancer treatment within 4 weeks prior to entering the study or you still have bad side effects from previous therapies~* You have an active infection that requires treatment~* You are HIV positive or have a history of Hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ridaforolimus (MK8669) + dalotuzumab (MK0646)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ciclesonide on Exercise Induced Bronchoconstriction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* stable asthma not on maintenance asthma medications~* exercise induced bronchoconstriction on dry air exercise challenge.~Exclusion Criteria:~* other significant co-morbidity or treatments that might interfere with the conduct or results of the study~* fail to return to baseline after a maximum washout period of 8 weeks~* unable to perform the procedures of the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): ciclesonide 50 and 200ug
- 2 (Type: ACTIVE_COMPARATOR): ciclesonide 100ug and 400ug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* A clinical diagnosis of hereditary angioedema Type 1 or Type 2, defined as having a C1-INH functional level and a C4 level below the lower limit of the normal (LLN) reference range, as assessed during the Screening period.~* Subject weight of ≥ 40 kg~* Access to and ability to use one or more acute medications approved by the relevant competent authority for the treatment of acute attacks of HAE~* Subjects must be medically appropriate for on-demand treatment as the sole medicinal management for their HAE during the study.~* Subjects must have a specified number of investigator-confirmed attacks during the run-in period of a maximum of 56 days from the Screening visit.~* Acceptable effective contraception~* Written informed consent~Key Exclusion Criteria:~* Pregnancy or breast-feeding~* Any clinically significant medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study~* Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study~* Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology~* Use of C1-INH within 14 days or use of androgens or tranexamic acid within 28 days prior to the Screening visit for prophylaxis of HAE attacks, or initiation of these drugs during the study~* Current participation in any other investigational drug study or received another investigational drug within 30 days of the Screening visit~* Prior enrollment in a BCX7353 study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BCX7353 110 mg once daily (Type: EXPERIMENTAL): BCX7353 administered as oral capsules once daily
- BCX7353 150 mg once daily (Type: EXPERIMENTAL): BCX7353 administered as oral capsules once daily
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo administered as oral capsules once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven cervical cancer~* Squamous, Adenosquamous, Adeno carcinoma cell type~* International Federation of Gynecologic Oncology (FIGO) stage IIB - IVA~* Gynecologic Oncology Group (GOG) performance status 0 - 2~Exclusion Criteria:~* Previous history of chemotherapy or radiation~* History of other cancer~* Hypersensitivity to platinum agents~* Pregnancy~* Serious medical disease

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- weekly cisplatin (Type: ACTIVE_COMPARATOR): Weekly cisplatin 40mg/m2 during radiation therapy
- tri-weekly cisplatin (Type: EXPERIMENTAL): cisplatin 75mg/m2 three cycles, every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary osteoarthritis in the hip, knee, hand, or spine~* Requiring NSAID therapy~Exclusion Criteria:~* Secondary OA with history and/ or any evidence of the following diseases: rheumatoid arthritis, uncontrolled gout, inflammatory joint disease, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, heritable disorders (e.g. hypermobility), collagen gene mutations, primary fibromyalgia (secondary fibromyalgia is allowed if in the opinion of the investigator it will not interfere with the patient's OA pain assessment), and systemic lupus erythematosus~* History and/ or any evidence of the following diseases in the target joint: septic arthritis, gout, recurrent episodes of pseudogout, Paget's disease of the bone, and articular fracture. If the patient has history of these conditions, then patient should only be excluded if the target joint is affected.~* History of severe adverse reactions of any kind under lumiracoxib or celecoxib treatment.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged 65 years or older on the day of vaccination and able to fulfill study requirements.~Exclusion Criteria:~* Previous vaccination with any licensed or experimental pneumococcal vaccine~* Residence in a nursing home, long-term care facility, or similar facility~* Known hypersensitivity to vaccination~* Immune deficiency or suppression

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- 13-valent pneumococcal conjugate vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete